[go: up one dir, main page]

PT973546E - Formulacoes estabilizadas de virus de papiloma humano - Google Patents

Formulacoes estabilizadas de virus de papiloma humano

Info

Publication number
PT973546E
PT973546E PT98915319T PT98915319T PT973546E PT 973546 E PT973546 E PT 973546E PT 98915319 T PT98915319 T PT 98915319T PT 98915319 T PT98915319 T PT 98915319T PT 973546 E PT973546 E PT 973546E
Authority
PT
Portugal
Prior art keywords
stabilized formulations
papiloma virus
human papiloma
formulations
human
Prior art date
Application number
PT98915319T
Other languages
English (en)
Inventor
Gautum Sanyal
David B Volkin
Li Shi
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9709351.2A external-priority patent/GB9709351D0/en
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of PT973546E publication Critical patent/PT973546E/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5258Virus-like particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/20011Papillomaviridae
    • C12N2710/20022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/20011Papillomaviridae
    • C12N2710/20023Virus like particles [VLP]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/20011Papillomaviridae
    • C12N2710/20034Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Plant Substances (AREA)
PT98915319T 1997-04-08 1998-04-07 Formulacoes estabilizadas de virus de papiloma humano PT973546E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4280897P 1997-04-08 1997-04-08
GBGB9709351.2A GB9709351D0 (en) 1997-05-07 1997-05-07 Stabilized human papillomavirus formulations

Publications (1)

Publication Number Publication Date
PT973546E true PT973546E (pt) 2004-06-30

Family

ID=26311501

Family Applications (1)

Application Number Title Priority Date Filing Date
PT98915319T PT973546E (pt) 1997-04-08 1998-04-07 Formulacoes estabilizadas de virus de papiloma humano

Country Status (18)

Country Link
EP (1) EP0973546B1 (pt)
JP (1) JP4598201B2 (pt)
KR (1) KR20010006169A (pt)
CN (1) CN1259051A (pt)
AT (1) ATE261734T1 (pt)
AU (1) AU739829B2 (pt)
CA (1) CA2286294A1 (pt)
DE (1) DE69822452T2 (pt)
DK (1) DK0973546T3 (pt)
EE (1) EE9900612A (pt)
ES (1) ES2216280T3 (pt)
IL (1) IL132201A0 (pt)
NO (1) NO994879L (pt)
NZ (1) NZ500028A (pt)
PL (1) PL336715A1 (pt)
PT (1) PT973546E (pt)
SK (1) SK138199A3 (pt)
WO (1) WO1998044944A2 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPP765398A0 (en) 1998-12-11 1999-01-14 University Of Queensland, The Treatment of papillomavirus infections
ES2313881T3 (es) * 1999-02-05 2009-03-16 MERCK & CO., INC. Formulaciones de vacunas frente al papilomavirus humano.
US6245568B1 (en) * 1999-03-26 2001-06-12 Merck & Co., Inc. Human papilloma virus vaccine with disassembled and reassembled virus-like particles
DE10137102A1 (de) 2001-07-30 2003-02-27 Deutsches Krebsforsch Polyvalente Vakzine gegen durch Papillomaviren verursachte Erkrankungen, Verfahren zu deren Herstellung und deren Verwendung
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
TW200806315A (en) * 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
DK2066354T3 (da) 2006-09-29 2013-05-27 Ligocyte Pharmaceuticals Inc Norovirus vaccine formuleringer
CN104740624B (zh) 2007-09-18 2018-04-24 武田疫苗股份有限公司 赋予针对诺如病毒的保护性免疫应答的疫苗
WO2009092113A2 (en) * 2008-01-19 2009-07-23 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for the delivery of vaccines to disrupted epithelium
CN103249431B (zh) * 2010-12-14 2016-11-02 葛兰素史密丝克莱恩生物有限公司 分枝杆菌抗原组合物
CN102085354A (zh) * 2010-12-30 2011-06-08 重庆大学 一种治疗人乳头瘤病毒16型引发的肿瘤的多肽药物
MY170746A (en) 2011-07-11 2019-08-27 Takeda Vaccines Inc Parenteral norovirus vaccine formulations
CN105177025B (zh) * 2013-12-03 2022-11-01 北京康乐卫士生物技术股份有限公司 18型重组人乳头瘤病毒病毒样颗粒及其制备方法
WO2016038625A2 (en) * 2014-09-11 2016-03-17 Cadila Healthcare Limited Superior human papilloma virus antigens with superior immunological properties and vaccine containing it
CN106701797B (zh) * 2015-08-12 2021-06-15 北京康乐卫士生物技术股份有限公司 31型重组人乳头瘤病毒病毒样颗粒及其制备方法
CN106399329B (zh) * 2015-08-12 2021-06-11 北京康乐卫士生物技术股份有限公司 33型重组人乳头瘤病毒病毒样颗粒及其制备方法
CN108201623A (zh) * 2016-12-19 2018-06-26 无锡鑫连鑫生物医药科技有限公司 人乳头瘤病毒重组四价疫苗、其制备方法及其应用
CN113347987A (zh) * 2018-11-28 2021-09-03 总医院公司 针对共生病毒的t细胞导向的抗癌疫苗

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2949031A1 (de) * 1978-12-15 1980-07-17 Sandoz Ag Vakzine
US4606918A (en) * 1983-08-22 1986-08-19 Syntex (U.S.A.) Inc. Polyoxypropylene-polyoxyethylene block polymer based adjuvants
JPS63239234A (ja) * 1988-01-14 1988-10-05 Green Cross Corp:The ワクチン製剤
JPH085803B2 (ja) * 1988-11-10 1996-01-24 武田薬品工業株式会社 日本脳炎ワクチンの製造法
US5904925A (en) * 1993-12-09 1999-05-18 Exner; Heinrich Adjuvant for antigens, and process for making
AUPM566794A0 (en) * 1994-05-17 1994-06-09 University Of Queensland, The Process and product
AR004464A1 (es) * 1994-11-14 1998-12-16 Merck Sharp & Dohme Un metodo para producir una proteina de capside de papilomavirus
IL117459A (en) * 1995-03-22 2005-11-20 Merck & Co Inc Dna encoding human papillomavirus type 18
IL117591A0 (en) * 1995-03-30 1996-07-23 Merck & Co Inc Synthetic DNA encoding human papillomavirus type 11 L1 protein
US5718904A (en) * 1995-06-02 1998-02-17 American Home Products Corporation Adjuvants for viral vaccines

Also Published As

Publication number Publication date
JP4598201B2 (ja) 2010-12-15
IL132201A0 (en) 2001-03-19
ES2216280T3 (es) 2004-10-16
NZ500028A (en) 2001-08-31
WO1998044944A2 (en) 1998-10-15
NO994879L (no) 1999-12-07
ATE261734T1 (de) 2004-04-15
EE9900612A (et) 2000-08-15
SK138199A3 (en) 2000-06-12
PL336715A1 (en) 2000-07-03
AU739829B2 (en) 2001-10-18
DE69822452T2 (de) 2006-04-20
EP0973546B1 (en) 2004-03-17
CA2286294A1 (en) 1998-10-15
KR20010006169A (ko) 2001-01-26
DE69822452D1 (de) 2004-04-22
JP2001519814A (ja) 2001-10-23
AU6953398A (en) 1998-10-30
NO994879D0 (no) 1999-10-07
EP0973546A2 (en) 2000-01-26
DK0973546T3 (da) 2004-06-28
WO1998044944A3 (en) 1998-12-30
CN1259051A (zh) 2000-07-05

Similar Documents

Publication Publication Date Title
PT973546E (pt) Formulacoes estabilizadas de virus de papiloma humano
TR200302105T4 (tr) Siklosporin, hiyalüronik asit ve polisorbat içeren göz formülasyonları.
JO3404B1 (ar) تركيبة صيدلانية سائلة تحتوي على مشتقات اريثروبويتين
DE69531314D1 (de) Verwendung von metallionen chelatoren zur stabilisierung von interferon-enthaltenden pharmazeutischen zubereitungen
BR0108173A (pt) Composições farmacêuticas de toxina de botulina
CY1113609T1 (el) ΔΙΑΛΥΤΟΤΗΤΑ ΙFΝ-ΒΗΤΑ-1b ΣΕ ΔΙΑΛΥΜΑΤΑ ΧΛΩΡΙΟΥΧΟΥ ΝΑΤΡΙΟΥ
NZ510887A (en) Formulations of fexofenadine for ocular and nasal delivery
DK1259226T3 (da) Anæstetiske formuleringer
DK1079803T3 (da) Proteinholdige præparater
NO922953L (no) Rekombinant fremstilt blodfaktorer og fremgangsmaate for ekspresjon av blodfaktorene, samt vacciniavirusrekombinanter
FR2857267B1 (fr) Formulation stabilisante et solubilisante pour les proteines cryoprecipitables.
CA2060560A1 (en) Method for insuring adequate intracellular glutathione in tissue
MXPA05009135A (es) Formulaciones liquidas de las proteinas de union del factor necrosis del tumor.
UY27373A1 (es) Formulaciones de interferón beta-humano
DE69933875D1 (de) Protein-verabreichungssystem, das dem menschlichen papillomavirus ähnliche partikel benützt.
ATE341339T1 (de) Zusammensetzungen von rekombinanten papillomavirus vakzinen
DE69535787D1 (de) Verbesserte dnase flüssige lösungen
EA199900915A1 (ru) Стабилизированные композиции вируса папилломы человека
SE8402199L (sv) Farmaceutiskt preparat innehallande co-dergocrin och en kalciumantagonist
DE69926633D1 (de) Injizierbare arzneiformulierungen von partricin derivaten
RU94032143A (ru) Композиция, содержащая препарат коагуляционного фактора viii, способ ее получения и применение поверхностно-активного вещества в качестве стабилизатора
SE9904132D0 (sv) Pharmaceutical composition for treatment of diarrhea
RU2003124254A (ru) Косметическое средство для ухода за кожей лица и шеи
DE60217302D1 (de) Erhaltung von körpereigenen proteinen